High Dose CHOP in Lymphoma

Phase II Study of Short High-dose CHOP Chemotherapy for Aggressive Non-Hodgkin's Lymphoma

The study hypothesis is that intensification of CHOP by dose escalation of the most active drugs in the combination will improve treatment outcome. Patients with diffuse large-cell lymphoma are treated by high cyclophosphamide containing CHOP. The planned dose is 3000 mg/m2 which is 4 times the atandard one. Only 4 cycles are given.

Inclusion Criteria:

• large-cell non-Hodgkin's lymphoma
• IPI low-intermediate, high-intermediate and high or bulky mediastinum
• age 18-65

Exclusion Criteria:

• previous treatment for lymphoma
• serious concurrent systemic disease